Form 4: Twist Bioscience Grants SVP Dennis Cho 25,465 RSUs

Twist Bioscience Corp. has granted its Senior Vice President, Chief Legal Officer & Corporate Secretary, Dennis Cho, 25,465 restricted stock units.

Summary

• Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp. (TWST), was granted 25,465 restricted stock units (RSUs).
• The transaction date for the acquisition of these RSUs was November 18, 2025.
• The RSUs were acquired at a price of $0, which is typical for an equity grant.
• Following this transaction, Dennis Cho beneficially owns a total of 146,159 shares of common stock directly.
• The RSUs will vest over a 48-month period, with 1/16th of the total number vesting on each quarterly anniversary of November 20, 2025, contingent upon continuous service through each vesting date.

Sentiment

Score: 7

Explanation: The grant of RSUs to a key executive is a positive sign for executive retention and alignment with shareholder interests, reflecting standard compensation practices without indicating any immediate negative operational or financial issues.

Positives

• The grant of 25,465 restricted stock units to a key executive, Dennis Cho, aligns his interests with long-term shareholder value.
• The 48-month vesting schedule encourages executive retention and sustained performance, fostering stability in leadership.

Future Outlook

The vesting schedule for the RSUs extends over 48 months from November 20, 2025, indicating a long-term incentive structure designed to retain the executive and align their performance with the company's sustained growth.

Industry Context

Executive equity grants like Restricted Stock Units (RSUs) are a standard practice across the biotechnology and broader tech industries. These grants are crucial for attracting, retaining, and incentivizing key personnel, aligning their long-term performance with company growth and shareholder returns.

Comparison to Industry Standards

• The grant of RSUs to a Senior Vice President is a common compensation practice, comparable to similar grants observed at companies like Illumina or Moderna for their executive teams, aiming to foster long-term commitment.
• A 48-month vesting period is typical for executive equity awards in the biotech sector, often seen in companies like Regeneron Pharmaceuticals or Amgen, ensuring sustained executive engagement and retention.

Stakeholder Impact

• Shareholders: The grant aligns executive incentives with long-term shareholder value creation, potentially leading to better company performance.
• Employees: Standard executive compensation practices can positively influence overall employee morale and retention strategies within the company.

Next Steps

• The granted RSUs will vest quarterly over the next 48 months, starting from November 20, 2025, contingent on Dennis Cho's continuous service to the company.

Key Dates

Recommendation

This Form 4 reports a routine executive equity grant, which is a standard compensation practice and does not provide new information that would fundamentally alter the investment thesis for Twist Bioscience. It reinforces executive alignment with long-term company performance but does not present a catalyst for a 'buy' or 'sell' recommendation.

Keywords

Twist Bioscience, TWST, Dennis Cho, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Form 4, Equity Grant, Biotechnology